Gain Therapeutics’ (GANX) “Outperform” Rating Reaffirmed at Oppenheimer

Oppenheimer restated their outperform rating on shares of Gain Therapeutics (NASDAQ:GANX) in a research note published on Tuesday, Benzinga reports. They currently have a $9.00 target price on the stock.

Several other brokerages also recently issued reports on GANX. Chardan Capital reaffirmed a buy rating and issued a $6.00 price target on shares of Gain Therapeutics in a report on Wednesday, March 27th. HC Wainwright reissued a buy rating and issued a $9.00 price objective on shares of Gain Therapeutics in a research report on Monday, April 1st.

Gain Therapeutics Stock Up 6.9 %

GANX stock opened at $3.39 on Tuesday. The company has a market cap of $54.99 million, a P/E ratio of -1.98 and a beta of 0.43. Gain Therapeutics has a 52 week low of $2.00 and a 52 week high of $5.65. The company’s 50-day moving average price is $4.07 and its 200 day moving average price is $3.45. The company has a current ratio of 3.59, a quick ratio of 3.59 and a debt-to-equity ratio of 0.04.

Gain Therapeutics (NASDAQ:GANX) last announced its quarterly earnings results on Tuesday, March 26th. The company reported ($0.29) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.32) by $0.03. On average, research analysts expect that Gain Therapeutics will post -1.17 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director Jeffrey Scott Riley purchased 30,000 shares of the company’s stock in a transaction that occurred on Thursday, March 28th. The stock was purchased at an average price of $3.86 per share, with a total value of $115,800.00. Following the completion of the transaction, the director now owns 30,000 shares of the company’s stock, valued at approximately $115,800. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 11.00% of the stock is currently owned by company insiders.

About Gain Therapeutics

Gain Therapeutics, Inc, a clinical-stage biotechnology company, engages in the discovery and development of allosteric therapies. Its lead drug candidate, GT-02287 for the treatment of GBA1 Parkinson's disease is being evaluated in a Phase 1 clinical trial. Its drug discovery platform Magellan identifies novel allosteric binding sites on disease-implicated proteins and exploits untapped opportunities, by pinpointing pockets that cannot be found or drugged with current technologies.